EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HIV+ subjects co-infected with hepatitis B or C Safety and efficacy comparison of ABT-378/ritonavir versus nelfinavir from a phase III blinded randomized clinical trial



Treatment of HIV+ subjects co-infected with hepatitis B or C Safety and efficacy comparison of ABT-378/ritonavir versus nelfinavir from a phase III blinded randomized clinical trial



AIDS (Hagerstown) 14(Supplement 4): S124, October




(PDF 0-2 workdays service: $29.90)

Accession: 035980459

Download citation: RISBibTeXText



Related references

ABT-378/ritonavir versus nelfinavir in antiretroviral naive subjects Week 48 comparison in a phase III blinded randomized clinical trial. AIDS (Hagerstown) 14(Supplement 4): S7, October, 2000

Efficacy of ABT-378/r vs nelfinavir in antiretroviral -naive subjects Results of a phase III blinded randomized clinical trial. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 293, 2000

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Aids 18(11): 1529-1537, 2004

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370(9581): 49-58, 2007

Comparison of efficacy and safety of hyoscine butylbromide versus anisodamine for acute gastric or intestinal spasm-like pain: A randomized, double-blinded, multicenter Phase III trial. Journal of Digestive Diseases 18(8): 453-460, 2017

Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. Aids Research and Human Retroviruses 32(5): 452-455, 2016

Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. Aids Research and Human Retroviruses 26(8): 841-845, 2010

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. Aids Research and Human Retroviruses 21(9): 757-767, 2005

A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clinical Trials 2(2): 97-107, 2001

Safety and efficacy comparison of minocycline microgranules vs lymecycline in the treatment of mild to moderate acne: randomized, evaluator-blinded, parallel, and prospective clinical trial for 8 weeks. Journal of Drugs in Dermatology 13(6): 671-676, 2015

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial ChemoTherapy 66 Suppl 3(): Iii19-Iii32, 2011

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial ChemoTherapy 66 Suppl 3(): Iii33-Iii44, 2011

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Aids 22(12): 1389-1397, 2008

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials 17(2): 72-77, 2016

Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). Pediatric Infectious Disease Journal 33(9): 940-945, 2015